Oxytocin, friendship and dealing with emotions

Oxytocin, friendship and dealing with emotions - Oxytocin, friendship and dealing with emotions

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-000298-35-NL

Enrollment

180

Registered

2017-03-07

Start date

2017-05-01

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

There are no medical conditions or disease under investigation.

Interventions

Trade Name: Syntocinon nasal spray Product Name: Syntocinon Product Code: RVG 03716 Pharmaceutical Form: Nasal spray INN or Proposed INN: OXYTOCIN CAS Number: 50-56-6 Concentration unit: IU internatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 18-30 years, women Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 180 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0

Exclusion criteria

Exclusion criteria: pregnancy, breastfeeding, women with children, cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Main Objective: Main objective is to examine effects of oxytocin on stress reactivity;Secondary Objective: Combined effects of oxytocin and social support on stress reactivity: to examine whether oxytocin enhances the beneficial effects of social support;Primary end point(s): stress reactivity: heart rate reactivity, salivary cortisol levels and subjective stress measured with questionnaires. Stress reactivity of 4 groups of participants will be measured: 1) participants who receive intranasal oxytocin and receive social support from a friend during stress 2) participants who receive intranasal oxytocin and who do not receive social support from a friend during stress 3) participants who receive a placebo and receive social support from a friend during stress 4) participants who receive a placebooxytocin and who do not receive social support from a friend during stress Expected end point: reduced stress reactivity in the oxytocin condition, with most pronounced oxytocin effects when there is social support from a friend;Timepoint(s) of evaluation of this end point: we will examine effects of intranasal oxytocin on stress reactivity during a social stress test (a virtual version of the Trier Social Stress Test) and a physical stress test (the Cold Pressor Test). Stress levels will be measured before oxytocin administration, immediately after administration, during the stress tests and afterwards. Saliva will be collected to measure cortisol, heart rate will be measured with the VU-AMS device, and subjective stress will be measured with questionnaires.	—

Measure

Time frame

Main Objective: Main objective is to examine effects of oxytocin on stress reactivity;Secondary Objective: Combined effects of oxytocin and social support on stress reactivity: to examine whether oxytocin enhances the beneficial effects of social support;Primary end point(s): stress reactivity: heart rate reactivity, salivary cortisol levels and subjective stress measured with questionnaires. Stress reactivity of 4 groups of participants will be measured: 1) participants who receive intranasal oxytocin and receive social support from a friend during stress 2) participants who receive intranasal oxytocin and who do not receive social support from a friend during stress 3) participants who receive a placebo and receive social support from a friend during stress 4) participants who receive a placebooxytocin and who do not receive social support from a friend during stress Expected end point: reduced stress reactivity in the oxytocin condition, with most pronounced oxytocin effects when there is social support from a friend;Timepoint(s) of evaluation of this end point: we will examine effects of intranasal oxytocin on stress reactivity during a social stress test (a virtual version of the Trier Social Stress Test) and a physical stress test (the Cold Pressor Test). Stress levels will be measured before oxytocin administration, immediately after administration, during the stress tests and afterwards. Saliva will be collected to measure cortisol, heart rate will be measured with the VU-AMS device, and subjective stress will be measured with questionnaires.

—

Secondary

Measure	Time frame
Secondary end point(s): not applicable;Timepoint(s) of evaluation of this end point: we will examine effects of oxytocin on stress reactivity during a social stress test and a physical stress test. Stress levels will be measured before oxytocin administration, immediately after administration, during the stress tests and afterwards.	—

Countries

Netherlands

Contacts

Public ContactCenter of Research on Psychological

Tilburg University, Center of Research on Psychological and Somatic disorders

s.diesbergen@uvt.nl0031134662175

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026